Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life

被引:2
作者
Hill, Jennifer R.
Fine, Samson W.
Zhang, Jingbo
Eastham, James A.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[2] Lenox Hill Hosp, New York, NY 10021 USA
[3] Cornell Univ, Ithaca, NY 14853 USA
来源
NATURE CLINICAL PRACTICE UROLOGY | 2007年 / 4卷 / 08期
关键词
extraprostatic extension; prostatic neoplasms; radical prostatectomy;
D O I
10.1038/ncpuro0861
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background A 61-year-old male presented with a history of gradually rising PSA over several years. His PSA had increased from 3.3 to 7 ng/ml over 3 years. Investigations Digital rectal examination, prostate biopsy, bone scan, and endorectal MRI were carried out to confirm the diagnosis and evaluate the extent of the cancer, with subsequent histopathologic examination of the radical prostatectomy specimen. Diagnosis Preoperative clinical stage (based on the digital rectal examination alone) was cT3a. Biopsy demonstrated extraprostatic extension in one core (Gleason 9 [4 + 5]). Endorectal MRI suggested a large volume cancer with probable extraprostatic extension in the posterior midline at the apex. Examination of the radical prostatectomy specimen demonstrated a pT3aN0 prostate cancer (Gleason 4 + 3 = 7 with a minor component of Gleason pattern 5). Extraprostatic extension was seen in the right posterior apex in the area of the dominant tumor mass. Surgical margins and seminal vesicles were negative for cancer. Management Radical retropubic prostatectomy with preservation of both neurovascular bundles plus bilateral pelvic lymph node dissection was performed. Postoperative PSA has been nondetectable. The patient is continent and, with the aid of vardenafil HCl, has erections sufficient for intercourse.
引用
收藏
页码:451 / 454
页数:4
相关论文
共 8 条
[1]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[2]   Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer [J].
Carver, Brett S. ;
Bianco, Fernando J., Jr. ;
Scardino, Peter T. ;
Eastham, James A. .
JOURNAL OF UROLOGY, 2006, 176 (02) :564-568
[3]   The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[4]   The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy [J].
Hricak, H ;
Wang, L ;
Wei, DC ;
Coakley, FV ;
Akin, O ;
Reuter, VE ;
Gonen, M ;
Kattan, MW ;
Onyebuchi, CN ;
Scardino, PT .
CANCER, 2004, 100 (12) :2655-2663
[5]  
MORDKIN RM, 1996, ONCOLOGY WILLISTON P, V10, P1299
[6]   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 [J].
Pilepich, MV ;
Caplan, R ;
Byhardt, RW ;
Lawton, CA ;
Gallagher, MJ ;
Mesic, JB ;
Hanks, GE ;
Coughlin, CT ;
Porter, A ;
Shipley, WU ;
Grignon, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1013-1021
[7]   Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy [J].
van den Ouden, D ;
Hop, WCJ ;
Schröder, FH .
JOURNAL OF UROLOGY, 1998, 160 (04) :1392-1397
[8]   Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome [J].
Ward, JF ;
Slezak, JM ;
Blute, ML ;
Bergstralh, EJ ;
Zincke, H .
BJU INTERNATIONAL, 2005, 95 (06) :751-756